Vor Biopharma Inc. (NYSE:VOR) Receives $8.86 Consensus Price Target from Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have been given an average rating of “Buy” by the seven brokerages that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.86.

A number of analysts recently commented on VOR shares. Stifel Nicolaus dropped their price target on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Vor Biopharma in a report on Thursday, March 20th. Oppenheimer reissued an “outperform” rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. HC Wainwright decreased their price target on Vor Biopharma from $17.50 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Vor Biopharma Trading Down 1.7 %

Shares of NYSE VOR opened at $0.75 on Thursday. The firm has a market cap of $51.70 million, a price-to-earnings ratio of -0.46 and a beta of -0.40. The stock has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.01. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VOR. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Vor Biopharma in the 4th quarter worth approximately $33,000. Virtu Financial LLC bought a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $60,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at $80,000. Trustees of Columbia University in the City of New York bought a new position in shares of Vor Biopharma during the 4th quarter valued at $102,000. Finally, Northern Trust Corp raised its position in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the period. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.